China’s SFDA Rapid Response To Biopharmaceutical-Triggered Deaths Seen As Progress By Industry Observers
This article was originally published in PharmAsia News
Executive Summary
BEIJING - In a case that closely parallels FDA's investigation of the drug heparin, China's State FDA is now examining a biopharmaceutical that triggered severe adverse reactions in seven Chinese patients, six of whom have died
You may also be interested in...
China’s State FDA Loses Independence in Merger With Ministry Of Health
BEIJING - In a major revamping of China's drug regulatory system, China's State FDA will lose part of its rule-making authority during an ongoing merger with the Ministry of Health
China’s State FDA Loses Independence in Merger With Ministry Of Health
BEIJING - In a major revamping of China's drug regulatory system, China's State FDA will lose part of its rule-making authority during an ongoing merger with the Ministry of Health
China’s SFDA To Require Electronic Tags For All Domestic Drugs; Imported Pharmaceuticals Likely To Follow
BEIJING - China's State FDA has issued a series of regulations in recent months that will ultimately require all pharmaceuticals, biologics and medical devices produced domestically to carry electronic tags with essential identifying information